Table 3.

Association of standing hypotension (<110 mm Hg vs. ≥ 110 mm Hg) with adverse events stratified by hypertension category: The ARIC Study (1987–2019)

Outcomes	Normotensive (N = 6,024)	Stage 1 Hypertension (N = 1,600)	Stage 2 (or treated) Hypertension (N = 4,843)	P-trend
Fall	1.00 (0.90, 1.11)	1.22 (0.81, 1.83)	1.03 (0.88, 1.21)	0.42
Syncope	0.97 (0.87, 1.09)	1.17 (0.76, 1.79)	1.14 (0.97, 1.34)	0.035
CHD	0.83 (0.73, 0.95)	1.06 (0.65, 1.72)	1.03 (0.88, 1.21)	0.0008
Death	0.90 (0.83, 0.98)	1.20 (0.89, 1.62)	0.93 (0.83, 1.04)	0.33

Hypertension stages were defined as normotension SBP < 130 mm Hg/DBP < 80 mm Hg, Stage 1 hypertension SBP 130–139 mm Hg/DBP 80–89 mm Hg, and no antihypertension medication use, and stage 2 hypertension SBP ≥ 140 mm Hg/DBP ≥ 90 mm Hg, or antihypertensive medication use in the past 2 weeks (based on medication review). Values are given as hazards ratio (95% confidence interval). Adjusted for age, sex, race-center, estimated glomerular filtration rate, body mass index, resting heart rate, high-density lipoprotein cholesterol, total cholesterol, prevalent CHD, prior stroke, prevalent heart failure, diabetes mellitus status, hypertension status, self-reported dizziness, alcohol consumption, education level, leisure index, smoking status, antihypertensive medication use in the last 2 weeks, and use of diuretics, antidepressants, sedatives, hypnotics, antipsychotics, and cholesterol-lowering medications. Participants were followed up through December 31, 2019, for a median of 24 years of follow-up. Abbreviations: CHD, coronary heart disease; SBP, systolic blood pressure.